# A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease

> **NCT07231679** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ingenia Therapeutics INC** · enrollment: 94 (estimated)

## Conditions studied

- Healthy Volunteers
- Chronic Kidney Disease

## Interventions

- **DRUG:** IGT-303
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07231679
- **Lead sponsor:** Ingenia Therapeutics INC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-30
- **Primary completion:** 2026-10
- **Final completion:** 2027-01
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07231679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07231679, "A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07231679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*